Drug Database
QL

QL-1209 (QL1209 / QL 1209)

✓ Approved

Qilu Pharmaceutical · ERBB2 · 单克隆抗体

什么是 QL-1209?

QL-1209 是一种单克隆抗体,由Qilu Pharmaceutical研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Intravenous (IV)。

药物档案

商品名QL1209, QL 1209
公司Qilu Pharmaceutical
药物类别单克隆抗体, 抗体
分子靶点ERBB2
给药途径Injectable (Others), Intravenous (IV)
状态Approved

作用机制

分子靶点

QL-1209 作用于 1 个分子靶点:

ERBB2erb-b2 receptor tyrosine kinase 2 (NEU, CD340)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

QL-1209 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Breast cancer✓ Approved

相关研究文献

PubMedTechniques in coloproctology2026-11-16

Quadratus lumborum versus transversus abdominis plane block for postoperative analgesia in laparoscopic colorectal surgery: a systematic review and meta-analysis of randomized controlled trials.

Moqbel I I, Elshabrawi M N MN, Tawadros M M MM, Abdelmeguid A I AI et al.

Effective pain management after surgery is crucial for recovery following laparoscopic colorectal resection in enhanced recovery after surgery (ERAS) programs. While the transversus abdominis plane (TAP) block is commonly used, it may not fully address visceral pain. The quadratus lumborum (QL) block might provide better coverage for both somatic and visceral pain due to its ability to spread to the thoracolumbar fascia and paravertebral space. This study aims to compare the clinical outcomes of QL versus TAP blocks in laparoscopic colorectal surgery. The main outcome was total opioid use within 24 h. Secondary outcomes included early pain scores, time until the first rescue analgesic was needed, postoperative nausea and vomiting (PONV), length of stay, surgical complications, and side effects related to the blocks. We conducted a systematic literature search using PubMed, Cochrane CENTRAL, Web of Science Core Collection, and Scopus from database inception to 27 July 2025 for randomized controlled trials (RCTs) comparing QL and TAP blocks. Two reviewers independently screened the studies, extracted data, and assessed quality using the Cochrane Risk of Bias 2 tool. We calculated pooled estimates using a random-effects model and evaluated the reliability of the evidence on the basis of the grading of recommendations, assessment, development, and evaluation (GRADE) framework. Four RCTs (n = 419) met the inclusion criteria. Compared with the TAP block, the QL block led to lower opioid use within 24 h (MD [mean difference] -8.92 mg morphine equivalents; 95% CI -11.57 to -6.28) and reduced pain scores both at rest MD -0.25 (-0.37 to -0.21) and during movement MD -0.40 [-0.52 to -0.29]. Operative time numerically favored the QL block, but the pooled difference was not statistically significant. The rates of PONV (OR 0.54; 95% CI 0.25-1.19) and dizziness (OR 0.60; 95% CI 0.22-1.63) were not significantly different between the two groups. The evidence was rated high for PONV and operative time, and moderate for opioid consumption, pain at rest, pain during movement, and dizziness, reflecting downgrades for imprecision and, for opioid consumption and pain during movement, substantial-to-high heterogeneity (I2 85% and 93%, respectively). In laparoscopic colorectal surgery, the QL block shows better opioid-sparing effects and lower pain scores at rest and during movement than the TAP block. Operative time numerically favored the QL block but did not differ significantly between groups. Importantly, it does not lead to more adverse effects. These findings suggest that the QL block may be a useful opioid-sparing option within ERAS-based perioperative care, although larger multicenter RCTs are needed before routine preference over the TAP block can be firmly recommended.

PMID 43035539
阅读全文 →
PubMedScience signaling2026-11-10

Gq-coupled GPCRs mediate the oncogenic activity of Gαq-Q209L/P mutants in uveal melanoma cells.

Aumiller Jenna L JL, Luo Jiansong J, Komolov Konstantin E KE, Sosa Julie M JM et al.

G protein-coupled receptors (GPCRs) stimulate heterotrimeric G proteins (Gαβγ) to facilitate downstream signaling, termination of which relies on a glutamine (Q) residue at position 209 in G protein α subunits. In uveal melanoma (UM), the most common intraocular malignancy in adults, >90% of patients harbor Q209L (QL) or Q209P (QP) mutations in Gαq and Gα11 proteins. Although mutationally active Gα subunits are thought to signal independently of GPCRs, some constitutively active Gα subunits may retain the ability to bind to GPCRs. Here, we demonstrated that Gq-coupled GPCRs, including 5-hydroxytryptamine receptor 2B (HTR2B), enhanced the oncogenic signaling of Gαq-QL. Although HTR2B antagonists alone had little to no inhibitory effects, they enhanced the sensitivity of UM cells to the Gαq-specific inhibitor YM-254890, as measured by signaling, cell viability, and proliferation assays. Last, treatment of UM cells with HTR2B antagonists and low concentrations of YM-254890 shifted endogenous Gαq-QL/QP mutants into an inactive conformation to a greater extent than did YM-254890 alone. Our study demonstrates that Gq-coupled GPCRs enhance the oncogenicity of mutationally active Gαq proteins and that antagonism of HTR2B promotes an inactive state of Gαq-QL/QP that increases sensitivity to an inhibitor of Gαq.

PMID 43008099
阅读全文 →
PubMedPharmaceutical development and technology2026-10-31

pH/GSH-responsive dual chitosan/PLA-coated cobalt ferrite nanoparticles for targeted and selective quinidine delivery in hepatocellular carcinoma.

Anter Esraa E, Elshami Fawzya I FI, Shereef Hadeer A HA, Abdou Safaa N SN et al.

Drug repurposing using smart nanocarriers may help overcome chemoresistance and poor tumor selectivity in hepatocellular carcinoma (HCC). Here, a pH/GSH-responsive dual chitosan/polylactic acid coated cobalt ferrite nanoparticle system (QL-CS/PLA-CFO NPs) has been explored to deliver QL for treating HCC. QL-CS/PLA-CFO NPs were prepared via ionotropic gelation and w/o/w emulsion with high loading (64.8%) and excellent stability (+28.0 mV). Comparative formulations, chitosan-only QL-CS-CFO (50.9%, -10.5 mV) and nonmagnetic QL-CS/PLA (60.7%, -21.0 mV), elucidated the roles of coating architecture and magnetic core. QL-CS/PLA-CFO NPs released 10.8% at pH 7.4 versus ∼95% at pH 4.5 with 10 mM GSH over 180 h, following quasi-Fickian diffusion kinetics. Encapsulation increased the WI38/HepG2 IC₅₀ ratio from 1.12 to 1.93 through controlled endosomal release and protecting normal cells, with ∼1.2% hemolysis and enhanced DPPH antioxidants IC₅₀ (47.9 vs. 71.9 μg/mL for free QL). DNA-binding studies revealed PLA-CFO synergy, yielding 38-fold enhanced affinity versus free QL through a minor-groove binding mode. Molecular docking suggested a potential interaction between quinidine and the HCC-associated biomarker glypican-3 (PDB 3GJB), supporting future investigation of its biological relevance. QL-CS/PLA-CFO NPs represent a promising platform for selective QL delivery in HCC, warranting further in vivo evaluation.

PMID 42965930
阅读全文 →
PubMedSurgical endoscopy2026-10-31

Comparing quadratus lumborum and transversus abdominis plane blocks for pain control after open ventral hernia repair: a propensity score-matched analysis of the Abdominal Core Health Quality Collaborative.

Khomutova Alisa A, Budney Sarah S, Stadsvold Brianna B, Fuller Josephine J et al.

Transversus abdominis plane (TAP) blocks are commonly used to reduce postoperative pain after ventral hernia repair (VHR). However, quadratus lumborum (QL) blocks may provide improved pain control. While TAP blocks have been studied in VHR, no literature directly compares TAP and QL blocks for open VHR. A propensity score-matched analysis of the Abdominal Core Health Quality Collaborative (ACHQC) was performed for patients undergoing elective open VHR between January 2023 and July 2025 who received TAP or QL blocks. Outcomes included length of stay (LOS), post-discharge opioid use, patient-reported pain and quality of life, and 30-day complications and readmissions. After matching, 445 patients met inclusion criteria: 333 (75%) received TAP blocks and 112 (25%) received QL blocks. Median age was 62 years, and median BMI was 32 kg/m2. Most patients underwent myofascial release with retromuscular mesh placement. Hernia width was similar between groups (11 vs 12 cm, p = 0.6). Median LOS was 4 days in both groups (p = 0.07). At 30 days, 87% of TAP and 90% of QL patients reported no opioid use after discharge (p = 0.5). HerQLes scores were similar, but PROMIS-3a pain scores were higher in QL patients at 30 days (p = 0.006). Complications and readmissions were similar. This is the first study to compare the outcomes of QL and TAP blocks for patients undergoing open VHR. There was no difference in pain control between each group as measured by hospital LOS and post-discharge opioid consumption; however, QL block patients reported higher pain scores at 30 days.

PMID 42963407
阅读全文 →
PubMedBritish journal of anaesthesia2026-10-28

Regional analgesic techniques for postoperative pain after kidney transplantation: a systematic review and Bayesian meta-analysis.

Azem Karam K, Ofir Aviad Y AY, Heesen Philip P, Ronen Ariel A et al.

Pain after kidney transplantation is often severe, and graft function constrains the use of systemic analgesia. Previous syntheses of regional techniques pooled them as a class, combined donors with recipients, and did not use a minimal clinically important difference (MCID). We searched PubMed, Embase, and CENTRAL through 5 September 2026 for randomised trials of regional analgesia in adult kidney transplant recipients (PROSPERO CRD420261478933); a trial-registry search and network meta-analysis were added post hoc. Bayesian random-effects models with MCID-scaled priors yielded posterior probabilities of benefit and of exceeding the MCID, and certainty of evidence was assessed using the GRADE framework. Fourteen trials (903 participants) were included. Only quadratus lumborum (QL) and transversus abdominis plane (TAP) blocks could be pooled against control. Both yielded lower pain at every pooled time point, but no pairwise pain comparison reached 80% probability of exceeding the 1.0 point MCID. Opioid consumption at 24 h was lower with the QL block (-15.5 morphine milligram equivalents; 95% credible interval -23.6 to -6.7) and the TAP block (-10.5; -14.4 to -5.5), with each reduction exceeding the 5 mg MCID with a probability >97%. In the network meta-analysis, no difference between QL and TAP blocks in pain or opioid consumption reached 80% probability of exceeding the MCID. Graft function and safety data were too sparse to pool. Twelve eligible registered trials were unpublished; certainty of evidence was very low. Quadrtus lumborum and transversus abdominus plane blocks reduce pain and opioid consumption at 24 h, but only the reduction in opioid consumption has a high probability of being clinically important. Certainty of evidence is very low; no technique is preferred, and effects on graft function are unknown.

PMID 42946571
阅读全文 →
PubMedNucleic acids research2026-10-27

HGVD: Human Genetic Variation Database update 2026 with sequencing of 4344 genetically diverse Japanese individuals.

Murakami Yukari Y, Higasa Koichiro K

Population-scale genome resources remain biased toward European ancestry, limiting variant interpretation in underrepresented populations. Here, we expanded the Human Genetic Variation Database (HGVD), a free Japanese allele-frequency resource launched in 2013. HGVD v3.1 integrates 1209 exomes with whole-genome sequencing (WGS) data from 3135 Japanese individuals selected by principal component analysis (PCA) to span genetic diversity, providing aggregate variant statistics for 4344 individuals, 3248 genotyped individuals, and expression quantitative trait loci (eQTL) from 300 individuals. For research and clinical use, HGVD provides coordinated JBrowse-based browsers for GRCh37/hg19, GRCh38/hg38, and T2T-CHM13. The non-GRCh37 variant tracks were generated by liftOver from the GRCh37 call set. Variant frequencies, sample counts, and coverage are available across assemblies, whereas eQTL annotations are currently available only on hg19. A downloadable, graph-genome-ready structural-variant release is provided, and the new pathSTR portal reports population-level distributions for 68 medically relevant tandem-repeat loci, derived by applying STRdust to long-read Oxford Nanopore data from 1019 individuals of the 1000 Genomes Project remapped to T2T-CHM13. HGVD v3.1 supports population-matched interpretation of rare pathogenic and pharmacogenomic variants, comparison of repeat-expansion alleles with long-read reference distributions, and structural-variant-aware reference construction, supporting precision medicine for Japan and East Asian populations. HGVD is available at https://www.hgvd.genome.med.kyoto-u.ac.jp/.

PMID 42935248
阅读全文 →

注册免费账户还可查看另外 3396 篇文献

免费注册查看全部文献 →

了解更多QL-1209